Entrada Therapeutics IncNASDAQ:TRDA
- LAST PRICE12.4300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 12.4300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRDA |
|---|---|---|
| 09:32 ET | 339 | 12.79 |
| 10:42 ET | 200 | 12.77 |
| 11:22 ET | 100 | 12.72 |
| 11:44 ET | 200 | 12.58 |
| 12:32 ET | 970 | 12.42 |
| 01:14 ET | 400 | 12.54 |
| 01:33 ET | 200 | 12.54 |
| 01:35 ET | 100 | 12.58 |
| 01:42 ET | 131 | 12.6 |
| 01:48 ET | 200 | 12.635 |
| 01:51 ET | 1240 | 12.56 |
| 01:53 ET | 1649 | 12.52 |
| 02:09 ET | 720 | 12.39 |
| 02:11 ET | 1978 | 12.49 |
| 02:26 ET | 3015 | 12.73 |
| 02:27 ET | 100 | 12.575 |
| 02:31 ET | 205 | 12.57 |
| 02:44 ET | 400 | 12.66 |
| 03:05 ET | 324 | 12.49 |
| 03:41 ET | 1175 | 12.52 |
| 03:43 ET | 300 | 12.545 |
| 03:56 ET | 1562 | 12.57 |
| 03:59 ET | 700 | 12.43 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Entrada Therapeutics Inc | 417.7M | -48.9x | --- |
Heron Therapeutics Inc | 398.4M | -3.0x | --- |
Travere Therapeutics Inc | 414.8M | -1.1x | --- |
Avid Bioservices Inc | 431.9M | -37.6x | --- |
Kamada Ltd | 297.7M | 29.5x | -22.48% |
Anika Therapeutics Inc | 379.2M | -4.6x | --- |
Company Information
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.
Contact Information
- Headquarters
- One Design Center Place, Suite 17-500BOSTON, MA, United States 02210
- Phone
- 857-305-1825
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Kush Parmar
- President, Chief Operating Officer
- Nathan Dowden
- Chief Executive Officer, Director
- Dipal Doshi
- Chief Financial Officer, Treasurer
- Kory Wentworth
- Chief Scientific Officer
- Natarajan Sethuraman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $417.7M |
|---|---|
Revenue (TTM) | $129.0M |
Shares Outstanding | 33.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.25 |
Book Value | $7.25 |
P/E Ratio | -48.9x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2.45% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
